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Veterinary Parasitology 149 (2007) 239–245AbstractPrevious vaccination trials against Ostertagia ostertagi in cattle have demonstrated the protective capacity of a protein fraction
termed ES-thiol, which is enriched for activation-associated secreted proteins (ASPs) and cysteine proteases. In this study, ES-thiol
was subfractionated through Q-Sepharose anion exchange chromatography to determine whether the ASPs and/or the cysteine
proteases are responsible for the induced protection. Calves (seven/group) were immunized three times intramuscularly with
100 mg of ES-thiol or equivalent amounts of an ASP-enriched fraction, a cysteine protease-enriched fraction or a rest fraction, with
QuilA adjuvant. A negative control group only received QuilA. After the final immunization the animals were challenged with a
trickle infection of 25,000 infectious L3 larvae (1000 L3/day; 5 days/week). During a 2-month period the geometric mean
cumulative faecal egg count (FEC) of the ES-thiol group was reduced by 62% compared to the QuilA control group (P < 0.05).
Groups injected with the ASP-enriched, the cysteine protease-enriched and the rest fraction demonstrated a reduction in cumulative
FEC of 74, 80 and 70%, respectively (P < 0.01). Although no significant reductions in worm burdens were observed, adult male and
female worms were significantly smaller in all vaccinated groups (P < 0.05), except for maleworms from the ES-thiol group. These
results suggest the protective capacity of ASPs and the presence of other protective antigens in the ES-thiol fraction.
# 2007 Elsevier B.V. All rights reserved.
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The gastrointestinal nematode Ostertagia ostertagi
is responsible for large losses in cattle productivity.
Currently, control is mainly based on the use of
anthelmintics. However, the threat of anthelmintic
resistance encourages us to look for other means of
control, such as vaccination. Previous vaccination trials* Corresponding author. Tel.: +32 9 264 73 87; fax: +32 9 264 74 96.
E-mail address: yves.meyvis@ugent.be (Y. Meyvis).
0304-4017/$ – see front matter # 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.vetpar.2007.08.014have shown that immunizing calves with excretion-
secretion (ES) material from adult Ostertagia worms
affinity purified on a thiol-sepharose column results in a
significant reduction of 56–60% in cumulative faecal
egg counts (FECs) during 2 months after a first infection
with L3 larvae. This reduction was accompanied by a
significant reduction in worm length (Geldhof et al.,
2002, 2004). The most abundant proteins in this ES-
thiol fraction have been identified as activation-
associated secreted proteins (ASPs) (Geldhof et al.,
2003). ASPs belong to a group of evolutionary related
secreted proteins called the SCP/tpx-1/Ag5/PR-1/Sc7
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plants, mammals and nematodes. ASP molecules have
previously shown their protective capacity in vaccine
trials against Ancylostoma caninum (Ghosh et al., 1996;
Ghosh and Hotez, 1999; Sen et al., 2000), A. ceylanicum
(Goud et al., 2004; Mendez et al., 2005), Onchocerca
volvulus (MacDonald et al., 2004) and Haemonchus
contortus (Schallig et al., 1997a,b; Vervelde et al.,
2002). The exact function of the ASPs remains unclear,
although it is believed that they play a role in parasite
infection and transition to parasitism (Hawdon et al.,
1996). Two ASP molecules of O. ostertagi have been
described in ES-thiol, i.e. Oo-ASP-1 and Oo-ASP-2,
with a molecular weight around 30 kDa (Geldhof et al.,
2003).
Besides the ASPs, ES-thiol contains multiple
cysteine proteases with cathepsin L-like activity
(Geldhof et al., 2002). The function of these enzymes
is unknown, but they might enable the parasite to
destroy host tissue for feeding and penetration, and to
evade the host immune system (Tort et al., 1999). The
protective capacity of cysteine proteases has already
been demonstrated against Fasciola hepatica (Wijffels
et al., 1994; Dalton et al., 1996) and H. contortus
(Boisvenue et al., 1992; Knox et al., 1999, 2005;
Redmond and Knox, 2004).
At the moment it is unclear which of these ES-thiol
components are essential for rendering protection
against an O. ostertagi challenge infection, i.e. the
ASPs, the cysteine proteases or other so far unidentified
proteins present in the ES-thiol fraction. The objective
of the present study was to further fractionate the ES-
thiol fraction in its different components and determine
their protective capacity separately.
2. Materials and methods
2.1. Antigen fractionation
The protective ES-thiol fraction was purified as
described previously (Geldhof et al., 2002, 2004). A Q-
Sepharose column (Amersham, 1 ml bedvolume) was
equilibrated in 10 mM Tris–HCl, pH 7.4. ES-thiol was
applied to the column (1 ml/min). Unbound proteins
were collected and bound proteins were eluted by a
stepwise increase in NaCl concentration (25–50–75–
100–125–175–250–500–1000 mM). Aliquots of all
samples were analysed on a 10% SDS-PAGE under
reducing conditions followed by silver staining. The
presence of ASPs was demonstrated by running the
samples on a 10% SDS-PAGE under reducing condi-
tions and blotting onto a PVDFmembrane. The blot wasblocked for 2 h in 10% horse serum in PBS/Tween20
(PBST), probed overnight with rabbit anti-rASP serum
obtained by immunization with an E. coli recombinant
of Oo-ASP-1 (diluted 1/200 in 5% horse serum/PBST/
Visser et al., unpublished) and incubated for 2 h with
conjugate (Goat anti-rabbit-HRPO, Sigma; diluted 1/
5000 in 5% horse serum/PBST). ASPs were visualized
by adding 0.05% 3,3 diaminobenzidine tetrachloride in
PBS containing 0.01% H2O2 (v/v). Cysteine proteases
were monitored by incubating the samples with
synthetic Z-Phe-Arg-AMC as was done in a previously
described cathepsin assay (Geldhof et al., 2000).
Finally, the material was pooled into three different
subfractions, i.e. an ASP-enriched fraction, a cysteine
protease-enriched fraction and a rest fraction, followed
by a concentration step on an Amicon Ultra-15
membrane (Millipore; 10,000 MWCO). Protein con-
centrations were determined using the BCA method
(Pierce Chemical Co., Rockford, IL, USA). Ten
micrograms of ES-thiol and its subfractions were
analysed by Coomassie Blue Staining under reducing
conditions. The presence of ASP was verified using the
same Western blot as described above. Cysteine
protease activity was detected by gelatin substrate gel
under non-reducing conditions (Geldhof et al., 2000).
2.2. Vaccination trial
The vaccination trial was designed as previously
described (Geldhof et al., 2002, 2004). A Holstein cross-
breed population of 35 female helminth-free calves (8
months of age) was randomly divided in five groups of
seven animals. All animals were immunized three times
intramuscularly in the neck with a 3-week interval. One
group received 100 mg of ES-thiol per immunization in
combination with 750 mg of QuilA adjuvant. One group
received the same amount of QuilA with Tris-buffer
instead of antigen (i.e. negative control group). Three
remaining groups were immunized with the ASP-
enriched, cysteine protease-enriched and rest fraction,
respectively. The quantity of each subfraction injected
was equivalent to the respective amount received by the
group injectedwith ES-thiol. Serumwas taken from each
animal before the first immunization and 1week after the
second immunization. The animalswere challengedwith
a trickle infection of 25,000 infectious L3 larvae
(1000 L3/day; 5 days/week) which started at the day
of the third immunization. All calves were euthanized 3
weeks after the last infection. Parasitological parameters
(i.e. FECs,worm counts andworm lengths, percentage of
L4 larvae) were analysed as described in previous trials
(Geldhof et al., 2002, 2004).
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Fig. 1. Analysis of the collected ES-thiol and its subfractionation. (a)
Comparison of the protein profiles on a 10% SDS-PAGE under denatur-
ing conditions, visualized by Coomassie Blue Staining. (b) Detection of
ASPproteins usingWestern blottingand rabbit anti-rASPantibodies. (c)
Visualization of cysteineproteases and the effect of thecysteineprotease
inhibitorE64onagelatin substrategel incubatedatpH5.0 in thepresence
of 5 mM DTT. Molecular weights of standards are presented in kDa.2.3. Statistical analysis
Statistical analysis was performed as described
previously (Geldhof et al., 2002, 2004). Data are shown
as arithmetic means (S.E.M.) or geometric means
(+range). Indicators of worm fitness (i.e. FEC, worm
burden and length of adult worms) were expected to be
lower in vaccinated animals. A one-tailed Mann–
Whitney U-test for pairwise comparison was used to
determine significance between group means of
vaccinated animals and the adjuvant control. Prob-
ability values smaller than 0.05 were considered to
indicate significant differences. Furthermore, a Krus-
kal–Wallis test was performed to demonstrate sig-
nificance between group means of vaccinated animals.
Based on the Bonferroni correction, probability values
smaller than 0.01 were considered statistically sig-
nificant.
2.4. Antibody response
The antibody response to the individual antigen
preparations was tested using pooled sera from the
different groups collected 1 week after the second
immunization. Ten micrograms of ES-thiol and its
subfractions were separated on a 10% SDS-PAGE under
non-denatured conditions and blotted onto a PVDF
membrane. The blot was blocked overnight in 10%
horse serum (diluted in PBST), probed for 2 h with
pooled bovine serum (diluted 1/500 in 5% horse serum/
PBST), and incubated for 1 h with conjugate (Rabbit
anti-bovine-HRPO, Sigma; diluted 1/5000 in 5% horse
serum/PBST). Recognized proteins were visualized by
adding 0.05% 3,30-diaminobenzidine tetrachloride in
PBS containing 0.01% H2O2 (v/v).
3. Results
3.1. Antigen fractionation
The protein composition of ES-thiol and its three
subfractions on a coomassie-stained gel is shown in
Fig. 1a. The profile of ES-thiol was identical to
previously published results (Geldhof et al., 2002,
2004). The ASP-enriched fraction (eluted at 0–25–
50 mM) contained only one visible band at 30 kDa. Two
protein bands were detected in the cysteine protease-
enriched fraction (eluted at 250–500–1000 mM) at 28
and 45 kDa. The rest fraction (eluted at 100–125–
175 mM) showed multiple protein bands over the entire
length of the gel, including a more abundant band at
48 kDa.
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Fig. 2. Geometric mean of the faecal egg output during the 2-month
period of the vaccination trial. (a) Animals vaccinated with QuilA
versus ES-thiol; (b) groups vaccinated with QuilA versus ASP-
enriched, cysteine protease-enriched and rest fraction.The Western blot analysis with antibodies against
ASP is shown in Fig. 1b. The 30 kDa band seen in the
ASP-enriched fraction was confirmed to be ASP. No
ASP proteins could be detected in the cysteine protease-
enriched fraction. Minor recognition was seen in the
rest fraction, possibly indicating trace amounts of ASP.
Fig. 1c shows the cysteine protease activity in the
different fractions as detected on a gelatine substrate gel
before and after addition of E-64, a cysteine protease
inhibitor. Cysteine protease activity present in the ES-
thiol fraction was highly enriched in the cysteine
protease-enriched fraction. The ASP-enriched fraction
did not contain any activity, while minor activity was
seen in the rest fraction. Addition of an E-64 inhibitor
completely abolished protease activity.
3.2. Vaccination trial
None of the animals showed adverse reactions to the
immunizations and no clinical signs of ostertagiosis
were observed. FECs during the vaccination trial are
shown in Fig. 2. The geometric mean FEC of all
vaccinated groups were lower than the control group
throughout the experiment. The parasitological para-
meters are summarized in Table 1. Immunization with
ES-thiol gave a statistically significant reduction in
cumulative FEC of 62%. Groups injected with the ASP-
enriched, cysteine protease-enriched and the rest
fraction showed a reduction in cumulative FEC of
74, 80 and 70%, respectively. The percentage of L4
larvaewas lower than 2% in all groups and no difference
could be seen between the different groups (data not
shown). Animals immunized with ASPs and cysteine
proteases, respectively contained 47 and 28% fewer
adult worms compared to the controls, although these
reductions were not significant. No reduction in worm
burden was observed in the ES-thiol group and the rest
fraction group. Both female and male worms were
significantly smaller in all treated groups with theTable 1
Parasitological parameters of the vaccination trial
Group n Cumulative FEC (EPG) Reduction (%) Num
QuilA 7 2034 (650–4575) – 273
ES-thiol 7 768* (63–2650) 62 289
ASP 7 538** (125–1250) 74 144
CYS 7 407** (75–1363) 80 179
REST 7 618** (238–2075) 70 253
F, female, M, male. Number of animals per group (n), geometric mean cu
(geometric mean + range) and worm lengths (geometric mean of 50 worm
* P < 0.05.
** P < 0.01.exception of male worms found in ES-thiol injected
animals. No significant difference was seen between the
parasitological parameters of the vaccinated groups.
3.3. Antibody response
Fig. 3 shows antibody recognition of non-denatured
ES-thiol and its subfractions by pooled sera from each
group. Animals injected solely with QuilA did not
recognize any ES-thiol proteins.
The ES-thiol group recognized ES-thiol proteins over
the entire length of the gel with one immunodominantber of worms Worm length (mm)
8 (550–8900) F 9.29, M 7.41 (8.95–9.92), (6.97–7.92)
1 (1450–5050) F 8.26*, M 6.65 (6.87–9.11), (5.26–7.71)
6 (400–5400) F 8.22**, M 6.91* (7.65–8.91), (6.15–7.57)
7 (100–4500) F 8.14**, M 6.78* (7.33–9.03), (5.87–7.70)
6 (450–6200) F 8.24**, M 7.03* (7.93–8.58), (6.73–7.50)
mulative egg counts (eggs per gram, EPG), total number of worms
s per animal + range).
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Fig. 3. Detection of serum antibody responses to vaccinations using Western blotting. Sera from individual animals were taken 1 week after the
second immunization and pooled for each group (QuilA, ES-thiol, ASP-enriched fraction, cysteine protease-enriched fraction and rest fraction).
Lanes were loaded with equivalent amounts of ES-thiol (ES-T), ASP-enriched fraction (A), cysteine protease-enriched fraction (C) and rest fraction
(R) in order to detect cross-reactivity.band at 120 kDa. Multiple bands were recognized in the
subfractions: two bands at 25 and 50 kDa in the ASP-
enriched fraction, a band at 120 kDa in the cysteine
protease-enriched and the rest fraction, and an additional
250 kDa band in the cysteine protease-enriched fraction.
Animals immunized with the ASP-enriched fraction
showed one immunodominant band at 50 kDa and a
minor band at 25 kDa in both the ES-thiol and the ASP-
enriched fraction. These bands were cut from a non-
denatured coomassie-stained gel and both were
identified as ASP-1 by mass-spectrometry (results not
shown). No proteins were recognized in the cysteine
protease and rest fraction.
Animals injected with the cysteine protease-enriched
fraction and the rest fraction showed a similar pattern.
Two high molecular weight bands around 120 and
250 kDa were recognized in the cysteine protease-
enriched fraction. The same 120 kDa band was detected
in the rest fraction. Recognition of the 120 kDa band by
the rest fraction group was stronger compared to the
cysteine protease group. None of the animals recog-
nized proteins from the ASP-enriched fraction.
4. Discussion
Published data on successful vaccination trials against
O. ostertagi are still scarce. Smith et al. (2000) previously
reported a reduction in egg output of 30–50% by
vaccination with gut membrane glycoproteins. More
recently, Vercauteren et al. (2004) reported the protective
capacity of a secreted polyprotein allergen named OPA.
Injection with this ES antigen induced a reduction infaecal egg output of 60% compared to control animals.
Finally, the ES-thiol fractionwas previously tested in two
independent trials, with themain protective effect being a
reduction in cumulative egg counts of 56–60% (Geldhof
et al., 2002, 2004). In the present study, injectionwithES-
thiol resulted in a reduction in cumulative faecal egg
counts of 62%, demonstrating the protective capacity of
ES-thiol for a third time.
Analysis of the composition of ES-thiol previously
indicated the presence of ASPs and cysteine proteases
(Geldhof et al., 2002). Both classes of molecules are
well known vaccine candidates, which have shown their
protective capacity in different host–parasite systems.
Animals injected with the ASP-enriched fraction
showed a 74% reduction in cumulative FEC. Analysis
of this fraction on gel and Western blot only
demonstrated the presence of ASPs. As far as we
know, this is the first time native ASPs from any parasite
were tested in a vaccine trial in such a pure form. The
only other native ASP tested as a vaccine candidate was
the 24 kDa single-domain ASP-2 homologue (Hc24)
from the sheep parasite H. contortus (Schallig et al.,
1997b). Adult sheep injected with this protein fraction
showed a 77.1% reduction in mean FEC and a 85.0%
reduction in worm count compared to animals injected
with only adjuvant. However, it is unclear if the Hc24
protein itself was actually responsible for the induced
protection, since the protein fraction also contained an
immunogenic 15 kDa antigen.
The cysteine protease-enriched fraction conferred an
80% reduction in cumulative FEC, which is the highest
level of protection induced against O. ostertagi in cattle
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protease activity were seen on a gelatine substrate gel,
suggesting the presence of at least three different
cysteine proteases. Protection induced by purified
native cysteine proteases has also been described in
vaccination trials against H. contortus (Redmond and
Knox, 2004; Knox et al., 2005). Sheep injected with
cysteine proteases obtained through anion exchange
(MonoQ) or affinity chromatography with cystatin (a
natural cysteine protease inhibitor) showed a reduction
of 28–56% in mean FEC and a reduction of 33–46% in
worm burden. However, integral membrane cysteine
proteases from O. ostertagi did not induce protection
(Geldhof et al., 2002), although it is not clear whether
these cysteine proteases are identical to those present in
ES-thiol. Furthermore, it is important to note that the
cysteine protease-enriched fraction used in this study
also contained other proteins. Therefore, it cannot be
concluded that the O. ostertagi cysteine proteases alone
are responsible for protection. Further purification of
this protein fraction is therefore essential. One
possibility would be to affinity purify these proteases
according to the method described by Redmond and
Knox (2004) using the parasite’s cystatin as a ligand.
The rest fraction contained the remaining proteins
present in ES-thiol and was still a fairly complex
mixture. Except for trace amounts of ASPs and cysteine
proteases, the other components remain unknown.
Protection rendered by this fraction could be attributed
to ASPs, cysteine proteases or other so far unknown
antigens. Further fractionation combined with a
complete proteomics analysis will be essential in order
to identify these unknown components and to test their
protective capacities separately.
Surprisingly, all subfractions induced a similar level
of protectionwith 70–80% reduction in cumulative FEC.
This might suggest the presence of common protective
antigens present in the different subfractions. Although
the subfractions were acquired from the anion exchange
columnunder awide salt gradient, one cannot exclude the
possibility that trace amounts of some proteins are
present in all fractions. Alternatively, multiple protective
antigens could be present in the different subfractions.
For this reason, serum cross recognition of the different
groups was analysed on Western blot. The animals
injectedwith theASP-enriched fraction did not show any
cross-reactivity with other subfractions and only
recognized the ASPs. This observation, combined with
the protein profile of the ASP-enriched fraction, strongly
suggests that the ASPs are the protective component in
this fraction. The analysis also indicated the presence of a
common 120 kDa protein in both the cysteine protease-enriched and rest fraction. Unfortunately, this protein
could not be visualized by coomassie or silver staining.
Therefore, it could not be isolated for mass-spectrometry
and its identity still remains unknown.
The results presented in this study strongly suggest
that vaccination of calves with nativeO. ostertagi ASPs
induces a protective immune response against a
homologous challenge infection. This will enable us
to compare the protective capacity of future recombi-
nant ASPs to that of its native form. Recombinant ASP
molecules have been evaluated for A. caninum (Ghosh
et al., 1996; Ghosh and Hotez, 1999; Sen et al., 2000), A.
ceylanicum (Goud et al., 2004; Mendez et al., 2005), O.
volvulus (MacDonald et al., 2004) and H. contortus
(Vervelde et al., 2002). These recombinants were
produced in bacterial systems and the levels of
protection varied between 21 and 79% reduction in
parasite burden. Although bacterial recombinants of
parasite antigens have been used previously, expression
of cysteine-rich antigens often results in the production
of inclusion bodies, making it difficult to solubilise the
antigen. Another problemmight be the incorrect folding
of the ASPs, disabling the formation of possible
immunogenic epitopes and preventing proper recogni-
tion by the host. Switching to eukaryotic expression
systems such as yeast, insect or mammalian cells might
solve this problem. For example, Ac-ASP-1 and Ac-
ASP-2 were expressed in Pichia pastoris to render
soluble recombinant antigens at high yield and low cost
(Goud et al., 2004). Besides protein conformation, the
glycan structures present on the ASPs may also be
crucial for protection. Two putative N-glycosylation
sites have been described in O. ostertagi ASP-1 and
ASP-2 (Geldhof et al., 2003). The glycan structures
present on these sites might be important for the
recognition by the host immune system or essential in
the correct folding or the dimerization of the ASPs. In
this trial, animals immunized with the native ASPs
recognized two different forms: an immunodominant
dimeric form at 50 kDa and a monomer at 25 kDa. The
dimerization of ASP molecules might result in the
creation of additional epitopes, explaining its higher
immunogenicity on Western blot. Further research on
the protein conformation and glycosylation of the ASPs
will give valuable information to help in the selection of
an appropriate recombinant expression system.
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